Objective-Endothelium dysfunction is an initiating factor in atherosclerosis. A disintegrin and metalloproteinase 15 (ADAM 15) is a multidomain metalloprotease recently identified as a regulator of endothelial permeability. However, whether and how ADAM15 contributes to atherosclerosis remains unknown. Methods and Results-Genetic ablation of ADAM15 in apolipoprotein E-deficient mice led to a significant reduction in aortic atherosclerotic lesion size (by 52%), plaque macrophage infiltration (by 69%), and smooth muscle cell deposition (by 82%). In vitro studies implicated endothelial-derived ADAM15 in barrier dysfunction and monocyte transmigration across mouse aortic and human umbilical vein endothelial cell monolayers. This role of ADAM15 depended on intact functioning of the cytoplasmic domain, as evidenced in experiments with site-directed mutagenesis targeting the metalloprotease active site (E349A), the disintegrin domain (Arginine-Glycine-Aspartic acid→Threonine-Aspartic acidAspartic acid), or the cytoplasmic tail. Further investigations revealed that ADAM15-induced barrier dysfunction was concomitant with dissociation of endothelial adherens junctions (vascular endothelial [VE]-cadherin/γ-catenin), an effect that was sensitive to Src family kinase inhibition. Through small interfering RNA-mediated knockdown of distinct Src family kinase members, c-Src and c-Yes were identified as important mediators of these junctional effects of ADAM15. 
T he development of atherosclerosis is partially attributed to endothelial dysfunction and deregulated monocyte transendothelial migration. 1 The vascular endothelium provides a selective barrier that controls the traffic of plasma proteins and circulating cells across the blood vessel wall. A major determinant of endothelial paracellular permeability is the adherens junction composed of VE-cadherin, a transmembrane molecule that forms homophilic bonds on the cell surface with its intracellular segment facilitating connection to the actin-linking α-, β-, and γ-catenins and p120. 2 This junctional structure can be degraded by proteases 2, 3 or undergo conformational changes in response to biological or physical signaling, [4] [5] [6] leading to increased paracellular permeability and leukocyte transmigration.
The a disintegrin and metalloproteinase (ADAM) molecules are a family of transmembrane glycoproteins with multiple extracellular domains, including metalloprotease and disintegrin domains. Among the human ADAMs identified, ADAM15 is unique because of the presence of an Arginine-Glycine-Aspartic acid (RGD) motif in its disintegrin domain that binds α v β 3 and α 5 β 1 integrins. 7 Furthermore, ADAM15 is among the several members in this family exhibiting sheddase activity, conferred by zinc-binding protease active sites in their metalloprotease domain, enabling cleavage of cell surface proteins. 8 In addition to these characteristic extracellular domains, the C-terminal cytoplasmic tail (CT) contains consensus recognition sites for protein kinases and the Src homology (SH2 and SH3) adaptors, suggesting a potential role in intracellular signaling. 8, 9 Based on these structures, ADAM15 exerts diverse functions in various physiological and pathological processes, including shedding, integrin binding, and cell signaling transduction. 7, 8 Since the initial report of ADAM15 expression in human endothelial cells (ECs) 10 and animal micro/macrovessels, 11 evidence has emerged for a role of this molecule in regulating cell-cell adhesion 12 and vascular functions. 8, 9, 11 In particular, ADAM15 supports lung cancer metastasis by promoting tumor cell migration and angiogenesis. 9, 13 In addition, increased ADAM15 is detected in cytokine-stimulated ECs and in tissues during atherosclerosis, arthritis, and inflammatory bowel disease. 8, [15] [16] [17] Although these observations have suggested a pathological function of ADAM15 in inflammation, direct evidence regarding a specific role and mechanism of action in disease processes is deficient. Recently, our own investigations have implicated ADAM15 in endothelial barrier dysfunction. 18 In the present study, we provide novel evidence for a pathogenic role of ADAM15 in chronic vascular inflammation in a mouse model of atherosclerosis.
Methods
Additional details are available in the online-only Data Supplement. Figure I in the online-only Data Supplement). Male mice at 6 weeks of age were fed an atherogenic diet (Research Diet, New Brunswick, NJ) for 12 weeks, after which heart-aorta complexes were excised for assessment of lesion. Thoracic-abdominal aortas were fixed with 10% formalin, and aortic sinuses and arches were frozen and embedded for cryosectioning. Oil red O staining for lesion size, Picrosirius red staining for collagen, and immunohistochemical labeling for macrophages and smooth muscle cells were performed, as previously described. 19 All animal procedures were conducted in compliance with National Institutes of Health guidelines and approved by the Institutional Animal Care and Use Committee.
Apoe

Primary Culture of Aortic Endothelial Cells
Primary aortic endothelial cells were isolated from mice using positive immunoselection with a rat anti-mouse CD31 antibody.
19
Monocyte Isolation and Transmigration
Murine peripheral monocytes were separated via histopaque (Sigma, St. Louis, MO) gradient centrifugation, followed by negative selection (Stem Cell, BC, Canada). Transendothelial migration was examined, as previously described.
18
Albumin Transendothelial Flux
Albumin flux across endothelial monolayers in culture was measured as an indicator of barrier properties.
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Construction of ADAM15 Mutant cDNA and Transfection of HUVECs
Plasmid pcDNA containing C-terminal hemagglutinin-tagged human wild-type (WT) Adam15, 20 a gift from Dr Mark L. Day of the University of Michigan, was used as a template to generate ADAM15 mutants. This included substitution of alanine for glutamate at amino acid 349 (E349A) to render the metalloproteinase domain proteolytically dead, conversion of RGD motif at 484-486 to TDD to disrupt integrin binding, and truncation of the CT at tyrosine 715 (CT) to disrupt intracellular signaling. Figure  1A) . Similarly, ADAM15 deficiency led to a significant reduction in the intimal area of aortic arches ( Figure 1B ) and the aortic sinus ( Figure 1C ) in Apoe −/− mice. Consistent with the reduction in lesion size, plaque macrophage infiltration was observed to be decreased in ADAM15-deficient Apoe −/− mice (69% reduction; Figure 1D ). Absence of ADAM15 also resulted in a lower smooth muscle cell content (by 82%; Figure 1E ) and reduced collagen deposition (by 59%; Figure  1F ) compared with plaques of littermate control animals.
Statistical Analysis
Endothelial ADAM15 Mediates Monocyte Transmigration
The direct role of ADAM15 in EC function was examined in primary aortic ECs and peripheral monocytes isolated from Apoe −/− Adam15 +/+ and Apoe −/− Adam15 −/− mice. As indicated by Western blotting, ADAM15 protein was detected in abundance in aortic ECs; however, no significant expression was detected in monocytes ( Figure 2A ). Similar to mouse cells, human ECs displayed a high level of ADAM15; the protein was not detectable in human monocytes ( Figure 2B) . A flow cytometric analysis for cell surface expression of ADAM15 further supports the lack of ADAM15 in monocytes. Furthermore, there was no obvious expression of ADAM15 in other types of leukocytes, including neutrophils and lymphocytes (data not shown). Functionally, ADAM15 deficiency in ECs significantly attenuated transendothelial migration of monocytes in response to a monocyte chemoattractant protein-1 gradient ( Figure 3A) . Similarly, depletion of ADAM15 in human umbilical vein endothelial cells (HUVECs) via small interfering RNA significantly impaired monocyte transmigration across EC monolayers ( Figure 3B and Figure 
Cytoplasmic Domain Is Required for ADAM15-Mediated Monocyte Transendothelial Migration
With the aim of identifying the domains of ADAM15 important to facilitate monocyte transmigration, an array of mutated cDNA constructs for human ADAM15 were generated. The E349A mutant, in which alanine was substituted for the conservative glutamic acid, had a catalytically dead metalloprotease active site. The RGD→TDD mutation rendered the disintegrin-binding domain inactive, and truncation of the CT created a mutant deficient in intracellular signaling capabilities. Flow cytometry indicated a homogeneous increase of ADAM15 expression on the EC surface after transfection ( Figure 4A and Figure IID and IIE in the online-only Data Supplement). Indeed, both total ( Figure  4B ) and cell surface expression of ADAM15 were comparable between WT and mutant constructs. Overexpression of ADAM15 WT markedly increased monocyte transmigration ( Figure 4C ). Interestingly, E349A and TDD mutants also increased monocyte transmigration, albeit to a lesser degree ( Figure 4C ). In sharp contrast, overexpression of the CT mutant failed to affect monocyte transmigration across the endothelium ( Figure 4C ). Thus, although metalloprotease and integrin-binding activities may have a role in the full effect of ADAM15, a functional cytoplasmic C-terminus is an absolute requisite for the promotion of monocyte transendothelial migration. To eliminate any possible confounding effects of endogenous ADAM15 in HUVECs, the activities of the WT and mutant constructs were investigated in ECs isolated from Adam15 −/− mouse aorta. As a result of lower transfection rates, homogeneous overexpression was unobtainable in Adam15 
ADAM15 Regulates Junctional Organization in a Cytoplasmic Domain-Dependent Manner
Monocyte transmigration is closely linked to endothelial barrier integrity. Consistent with our previous data, 18 we report that overexpression of ADAM15 WT, E349A, or TDD constructs in HUVECs significantly increased the permeability coefficient of albumin P a ( Figure 5A ), an indicator of barrier function. The essential role of the ADAM15 cytoplasmic domain in endothelial barrier dysfunction was reinforced by a blunting of the ADAM15-induced hyperpermeability in cells transfected with the CT-truncated mutant ( Figure 5A ).
The characterization of ADAM15 as an adherens junction molecule 12 is supported by our imaging data showing both Figure 5B and 5C), further supporting the importance of the cytoplasmic domain in barrier regulation. The critical role of γ-catenin in the preservation of barrier integrity was further confirmed by evidence that small interfering RNA-mediated knockdown of γ-catenin in HUVECs resulted in increased permeability to albumin ( Figure 5E ) and monocyte transmigration ( Figure 5F ).
Given that ADAM15 had no shedding effect on VE-cadherin, 18 we sought to determine a signaling role in tyrosine phosphorylation of junction proteins. Western blotting showed significantly increased phosphorylation of VE-cadherin (at Y658) after ADAM15 overexpression in HUVECs ( Figure 
ADAM15 Signals Through c-Src and c-Yes to Mediate Junction Dissociation and Monocyte Migration
We previously reported that Src family kinase (SFK) and mitogen-activated protein kinases signaling may be involved in the endothelial hyperpermeability response to ADAM15. 18 In the present study, however, the SFK inhibitor PP2, but not the mitogen-activated protein kinases inhibitor U0126, prevented both the dissociation of γ-catenin from VE-cadherin ( Figure 6A ) and tyrosine phosphorylation of VE-cadherin ( Figure VIID in the online-only Data Supplement) in response to ADAM15 upregulation. Consistently, PP2 treatment of ECs also blocked ADAM15-induced monocyte transendothelial migration ( Figure 6B ). These data reveal a requirement for SFK activity in ADAM15-mediated endothelial junction responses and monocyte transmigration.
To identify specific SFK family members involved in these effects of ADAM15, Fyn, c-Src, or c-Yes expression was depleted in HUVECs via small interfering RNA ( Figure  6C ). Basal junction protein association was unaffected by all SFK member-specific small interfering RNAs ( Figure VIIC in the online-only Data Supplement). However, knockdown of c-Src or c-Yes but not Fyn reversed ADAM15-induced VE-cadherin/γ-catenin dissociation ( Figure 6E ) and monocyte transmigration ( Figure 6D ). In accord, c-Src-or c-Yesdepleted HUVECs showed attenuated VE-cadherin phosphorylation in response to ADAM15 overexpression ( Figure VIID in the online-only Data Supplement). Interestingly, knockdown of Fyn also decreased VE-cadherin phosphorylation in ADAM15-overespressed HUVECs.
Discussion
ADAM15 has been characterized as an adherens junction molecule 12 and implicated in cancer and chronic inflammatory disorders. 8, [15] [16] [17] Although correlative analyses showing increased abundance in inflammatory tissues and atherosclerotic lesions support its involvement in inflammation, the direct role of ADAM15 and its mechanistic contributions to particular disease processes remain to be evaluated. We demonstrate that ADAM15 deficiency is associated with attenuated vascular lesions, intimal hyperplasia, and macrophage infiltration in atherosclerotic mice. To the best of our knowledge, this constitutes the first line of evidence for a pathological role of ADAM15 in atherosclerosis. Consistent with these in vivo observations, cell experiments showed that overexpression of ADAM15 increased protein permeability and monocyte transmigration across endothelial monolayers, whereas depletion of ADAM15 resulted in the opposite. Furthermore, we report a novel signaling mechanism of 
ADAM15-induced endothelial barrier dysfunction mediated by its cytoplasmic domain and involving specific SFK (c-Src and c-Yes) activities.
The structural domains of ADAM15 confer diverse biological functions, including sheddase activity, integrin interactions, and cell signal transduction. The presence of a zinc-binding protease site in the extracellular metalloprotease domain renders endopeptidase activity. ADAM10 and ADAM17, close relatives of ADAM15, are known to cleave adhesion molecules involved in leukocyte transmigration, including VE-cadherin, vascular cell adhesion molecule-1, and Nectins. 3, [21] [22] [23] Although several substrates have been characterized as targets of ADAM15 sheddase activity, 13, 20, 24 our previous study indicated that ADAM15 did not cleave VE-cadherin. 18 In the present study, we further explored the sheddase activity of ADAM15 on the Ig superfamily cell adhesion molecules (intercellular adhesion molecule 1, Nectin-2, platelet endothelial cell adhesion molecule-1, and vascular cell adhesion molecule-1) with respect to their potential involvement in regulating monocyte-EC interactions during atherosclerosis development. The results showed that the presence or absence of ADAM15 in vivo did not alter the cell surface expression of these adhesion molecules and that in vitro overexpression or knockdown of ADAM15 in ECs did not affect the level of their soluble fragments (shedding products) in culture medium. These results, in combination with the finding that proteolytically dead ADAM15 increased endothelial permeability and monocyte transendothelial migration, suggest a role of ADAM15 in regulating monocyte-endothelium interactions, independent of its shedding activity.
Integrin signaling in cell-matrix focal adhesions regulates the barrier property of the vascular endothelium that controls the outward flux of plasma proteins (eg, low-density lipoprotein) and circulating leukocytes (eg, monocytes), cellular processes known to contribute to atherosclerotic plaque formation. ADAMs have the capability to interact with integrins through their disintegrin domain. 25 In particular, human ADAM15 contains an RGD motif that binds α v β 3 and α 5 β 1 integrins, thereby competitively inhibiting their binding to matrix substrates. 7 To investigate the specific contribution of this motif to barrier dysfunction, RGD was replaced with TDD in the disintegrin domain, and this mutant form of ADAM15 still increased endothelial permeability and monocyte transmigration in the same pattern as WT ADAM15. This corroborates the previous observation that mutation of murine ADAM15 in the same manner (RGD→TDD) did not affect binding to integrins. 26 On the other hand, it has been reported that RGD-blocking peptides inhibited ADAM15 binding to integrins in hematopoietic cells 27 and that RGD mutation decreased T-cell adhesion to intestinal epithelial cells. 28 The discrepancies may be because of different experimental conditions used in those studies. Alternatively, ADAM15 may interact with integrins in a manner that does not require the RGD motif. 27, 29 Interestingly, truncation of the CT blunted ADAM15-induced monocyte transmigration. We, therefore, pursued an alternative mechanism focusing on the cytoplasmic domain of ADAM15, which contains protein kinase-binding sequences involved in signal transduction. The endothelial adherens junction responds to a variety of physical forces and biological factors. Under inflammatory conditions, junction responses are characterized by weakened cell-cell adhesion and intercellular gap formation. 5 Rather than depending on junction protein degradation, this process can be a dynamic interaction triggered by intracellular signaling events. 30 In this regard, tyrosine phosphorylation of VE-cadherin and catenins is viewed as an important event upstream of junction dissociation upon stimulation by cytokines and neutrophils. 6, 31, 32 The current finding that ADAM15 phosphorylates and dissociates VE-cadherin/catenin complexes is indicative of a regulation of junction dynamics in a fashion similar to inflammatory mediators. A previous study suggested that dissociation of β-catenin from VE-cadherin is a key triggering event in junction signaling; 2 however, we found that γ-catenin/VE-cadherin dissociation appeared to be a dominant event in the ADAM15-mediated junction response. Depletion of γ-catenin led to hyperpermeability and enhanced monocyte transmigration. The importance of γ-catenin in preserving barrier function is supported by an in vitro study showing that stabilization of endothelial junctions in the presence of tyrosine phosphatase required γ-catenin but not β-catenin. 33 Also, an in vivo study demonstrated that γ-catenin is necessary for the maintenance of endothelial barrier integrity. 34 Our experiments with PP2, a pan inhibitor of SFK, indicated that ADAM15-induced VE-cadherin/γ-catenin dissociation is dependent on the tyrosine kinase activity of this family. SFKmediated protein tyrosine phosphorylation has been implicated in angiogenesis and inflammation, 31 where a functional link between the tyrosine kinase activity and endothelial hyperpermeability has been established. 5, [30] [31] [32] 35 The cytoplasmic C-terminus of ADAM15 bears putative recognition sites for tyrosine kinases and Src-homology (SH3/SH2) binding sequences. 10 In hematopoietic cells, ADAM15 C-terminus binds to SFK in a phosphorylation-dependent manner. 36 In cancer cells, splice variants of ADAM15 containing Srcbinding sequences were associated with enhanced catalytic activity and malignant tumor behavior. 24, 37 We propose that ADAM15 CT serves as a scaffold to recruit SFK into close proximity with junctional structures, where SFK-triggered signal transduction leads to VE-cadherin/γ-catenin dissociation. This hypothesis is supported by evidence of colocalization between ADAM15 and VE-cadherin observed in the present and previous studies. 12 Three SFK members, Fyn, c-Src, and c-Yes, have been identified in ECs. 38 The present finding that depletion of c-Src and c-Yes, but not Fyn, attenuated ADAM15-induced junction disruption and monocyte transmigration suggests that distinct SFKs have diverse roles in cellular events. In line with this, although vascular endothelial growth factor-mediated angiogenesis required SFK activity in general, vascular endothelial growth factor-induced endothelial hyperpermeability was dependent on c-Src and c-Yes but not Fyn. 39 Furthermore, it might be well recognized that tyrosine kinase activity plays a critical role in endothelial hyperpermeability, but whether adherens junction opening is consequential to tyrosine phosphorylation of VE-cadherin, and indeed which specific phosphorylation sites are involved, remains controversial. 2, 40 Given that knockdown of Fyn decreased VE-cadherin phosphorylation without recovering VE-cadherin/γ-catenin association in ADAM15-overexpressing ECs, it is unlikely that VE-cadherin phosphorylation at tyrosine 658 is a requisite of endothelial barrier disruption. In further support of this, knockdown of c-Yes decreased VE-cadherin phosphorylation to below basal levels ( Figure VIID in the online-only Data Supplement) without totally recovering VE-cadherin/γ-catenin association ( Figure 6E) .
In an effort to discern the relative importance of endothelial versus monocyte-derived ADAM15 in junction with dissociation and monocyte transmigration, we compared protein levels as well as cell surface expression of ADAM15 between ECs and leukocyte subpopulations from both human and mouse blood. Although abundant ADAM15 was detected in ECs, it was hardly detectable in monocytes or neutrophils, indicating a minimal contribution of leukocytic ADAM15 to the observed inflammatory response. Based on the absence of ADAM15 in monocytes and the data from in vitro experiments with EC-specific ADAM15 knockdown, we suggest that endothelium-derived ADAM15 plays an essential role in mediating endothelial barrier dysfunction and leukocyte infiltration during atherosclerosis.
It is noteworthy that along with decreased macrophage infiltration, deficiency of ADAM15 also resulted in reduced smooth muscle cell migration and collagen deposition into the lesion, which might be attributable to the fact that as a metalloprotease, ADAM15 is capable of digestion of type IV collagen 41 and regulation of cell migration. 13 These suggest that ADAM15 may also contribute to stenosis of the artery lumen during atherosclerosis.
In conclusion, we provide novel evidence that ADAM15 contributes to atherosclerosis at least, in part, by promoting endothelial barrier dysfunction and monocyte transmigration. Disruption of endothelial barrier integrity by ADAM15 involves induction of VE-cadherin phosphorylation coupled with VE-cadherin/γ-catenin dissociation. The junction response to ADAM15 is mediated by its cytoplasmic domain and requires c-Src and c-Yes activity. Although the current study contributes to a better understanding of both the molecular biology of ADAM15 and the pathophysiology of atherosclerosis, further investigation in this area is warranted to aid the identification of therapeutic targets for effective treatment and prevention of vascular inflammation.
